Bio
We haven't found any bio for you yet.
Researcher Links
Loading links...
Publications by Type
Loading publications…
The last 5 uploaded publications
Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma
Lotfi Benboubker, Meletios A Dimopoulos, Angela Dispenzieri, John Catalano, Andrew R. Belch, Michèle Cavo, Antonio Pinto, Katja Weisel, Heinz Ludwig, Nizar J. Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, Jamie Cavenagh, Catarina Geraldes, Je‐Jung Lee, Christine Chen, Albert Oriol, Javier de la Rubia, Lugui Qiu, Darrell White, Daniel Binder, Kenneth Anderson, Jean-Paul Fermand, Philippe Moreau, Michel Attal, Robert Knight, Guang Chen, Jason Van Oostendorp, Christian Jacques, Annette Ervin‐Haynes, Hervé Avet‐Loiseau, Cyrille Hulin, Thierry Façon (2014). Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with Myeloma. , 371(10), DOI: https://doi.org/10.1056/nejmoa1402551.
Article35 days agoInitial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT)
Thierry Façon, Meletios A Dimopoulos, Angela Dispenzieri, John Catalano, Andrew R. Belch, Cyrille Hulin, Michèle Cavo, Antonella Pinto, Katja Weisel, Heinz Ludwig, Nizar J. Bahlis, Anne Banos, Mourad Tiab, Michel Delforge, James D. Cavenagh, Catarina Geraldes, Je‐Jung Lee, Christine I. Chen, Albert Oriol, Javier de la Rubia, Lugui Qiu, Darrell White, Daniel Binder, Kenneth C. Anderson, Philippe Moreau, Michel Attal, Robert Knight, Guang Chen, Jason Van Oostendorp, Christian Jacques, Annette Ervin‐Haynes, Lofti Benboubker (2013). Initial Phase 3 Results Of The First (Frontline Investigation Of Lenalidomide + Dexamethasone Versus Standard Thalidomide) Trial (MM-020/IFM 07 01) In Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts) Ineligible For Stem Cell Transplantation (SCT). , 122(21), DOI: https://doi.org/10.1182/blood.v122.21.2.2.
Article35 days agoLenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma
Asher Chanan‐Khan, Sagar Lonial, Donna Weber, Ivan Borrello, Robin Foà, Andrzej Hellmann, Meletios A Dimopoulos, Arlene S. Swern, Robert Knight (2012). Lenalidomide in combination with dexamethasone improves survival and time-to-progression in patients ≥65 years old with relapsed or refractory multiple myeloma. , 96(2), DOI: https://doi.org/10.1007/s12185-012-1125-7.
Article35 days agoEffects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone
Jesús F. San Miguel, Meletios A Dimopoulos, Edward A. Stadtmauer, S. Vincent Rajkumar, David S. Siegel, M. L. Casadebaig Bravo, Marta Olesnyckyj, Robert Knight, Jerome B. Zeldis, Jean‐Luc Harousseau, Donna M. Weber (2010). Effects of Lenalidomide and Dexamethasone Treatment Duration on Survival in Patients With Relapsed or Refractory Multiple Myeloma Treated With Lenalidomide and Dexamethasone. , 11(1), DOI: https://doi.org/10.3816/clml.2010.n.120.
Article35 days agoLonger Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma
Jesús F. San Miguel, Meletios A Dimopoulos, Edward A. Stadtmauer, S. Vincent Rajkumar, David S. Siegel, Marie‐Laure Casadebaig Bravo, Marta Olesnyckyj, Robert Knight, Jerome B. Zeldis, Jean‐Luc Harousseau, Donna M. Weber (2008). Longer Duration of Treatment and Maintenance of Best Response with Lenalidomide and Dexamethasone Prolongs Overall Survival in Patients with Relapsed or Refractory Multiple Myeloma. , 112(11), DOI: https://doi.org/10.1182/blood.v112.11.3702.3702.
Article35 days ago